Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Previous studies have identified several potential predisposing factors, including ventricular aneurysm, low LVEF, and alterations in coagulation and inflammatory markers. The relative weight of these ...

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...

We excluded studies with patients with edge-to-edge MVr, those with pre-existing indication for anti-coagulation, if patients received a concomitant cardiac procedure requiring anti-coagulation and ...

Medically reviewed by Soma Mandal, MD Petechiae are tiny red, purple, or brown spots on your skin, inside of your mouth, or ...

Thurner syndrome (MTS) is a clinicopathological condition where the left common iliac vein is compressed by the overlying right common iliac artery, potentially leading to deep vein thrombosis (DVT) ...

Although the 65 patients in the aPTT group received more heparin than the 66 patients in the anti-Xa group, and the daily mean aPTT was subtherapeutic in the anti-Xa group and therapeutic in the ...

Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke. (HealthDay News) — Subcutaneous injection of abelacimab ...

Xarelto is a brand name of the drug rivaroxaban. Medicare covers the cost of prescription medications, including Xarelto, under certain conditions. A person must be enrolled in a Medicare Part D ...

Background: Pediatric thrombosis is a relatively rare but severe condition in the field of pediatrics, with far-reaching consequences. Recent studies have indicated a rising incidence of this disease ...

1 Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China 2 Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of ...

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes than patients receiving a standard-of-care blood thinner, a new study has ...